Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.

被引：0

作者：

Nastoupil, Loretta J.

Kamdar, Manali K.

Chavez, Julio C.

Ghesquieres, Herve

Ghosh, Monalisa

Holmes, Houston

Guillermo, Armando Lopez

Martinez-Lopez, Joaquin

Novak, Urban

Ribrag, Vincent

Roddie, Claire

机构：

[1] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX USA

[2] Univ Colorado, Canc Ctr, Aurora, CO USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] Hop Lyon Sud, Lyon, France

[5] Univ Michigan Hlth Syst, Ann Arbor, MI USA

[6] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA

[7] Hosp Clin Barcelona, Barcelona, Spain

[8] Hosp 12 Octubre, Madrid, Spain

[9] Univ Hosp Bern, Med Oncol, Inselspital, Bern, Switzerland

[10] Gustave Roussy Canc Ctr DITEP, Villejuif, France

[11] UCL, London, England

[12] Emory Bone Marrow & Stem Cell Transplant Ctr, Winship Canc Inst, Atlanta, GA USA

[13] Hackensack Univ, Hackensack Meridian Hlth Sch Med, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA

[14] Mayo Clin, Phoenix, AZ USA

[15] Mem Sloan Kettering Canc Ctr, New York, NY USA

[16] Univ klinikum Carl Gustav Carus Dresden, Dresden, Germany

[17] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

[18] Bristol Myers Squibb Co, Celgene, Boudry, Switzerland

[19] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7526

引用

页数：1

共 50 条

[41] Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
Bishop, Michael R.
Dickinson, Michael
Purtill, Duncan
Barba, Pere
Santoro, Armando
Hamad, Nada
Kato, Koji
Sureda, Anna
Greil, Richard
Thieblemont, Catherine
Morschhauser, Franck
Janz, Martin
Flinn, Ian W.
Rabitsch, Werner
Kwong, Yok Lam
Kersten, Marie Jose
Minnema, Monique C.
Holte, Harald
Chan, Esther Hian Li
Martinez-Lopez, Joaquin
Mueller, Antonia M. S.
Maziarz, Richard T.
McGuirk, Joseph P.
Bachy, Emmanuel
Le Gouill, Steven
Dreyling, Martin
Harigae, Hideo
Bond, David A.
Andreadis, Charalambos
McSweeney, Peter A.
Kharfan-Dabaja, Mohamed A.
Newsome, Simon
Degtyarev, Evgeny
Del Corral, Chris
Andreola, Giovanna
Masood, Aisha
Schuster, Stephen J.
Jaeger, Ulrich
Borchmann, Peter
Westin, Jason R.
BLOOD, 2021, 138
[42] Tisagenlecleucel vs Standard of Care as Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III BELINDA Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 7 - 8
[43] Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Thorpe, Jerill
Jiang, Yue
Rytlewski, Julie A.
Kostic, Ana
Kim, Yeonhee
Peiser, Leanne
BLOOD, 2021, 138 : 3834 - +
[44] Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
Sehgal, Alison
Hoda, Daanish
Riedell, Peter A.
Ghosh, Nilanjan
Hamadani, Mehdi
Hildebrandt, Gerhard C.
Godwin, John E.
Reagan, Patrick M.
Wagner-Johnston, Nina
Essell, James
Nath, Rajneesh
Solomon, Scott R.
Champion, Rebecca
Licitra, Edward
Fanning, Suzanne
Gupta, Neel
Dubowy, Ronald
D'Andrea, Aleco
Wang, Lei
Ogasawara, Ken
Thorpe, Jerill
Gordon, Leo, I
LANCET ONCOLOGY, 2022, 23 (08): : 1066 - 1077
[45] Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain
Garcia-Sancho, Alejandro Martin
Presa, Maria
Pardo, Carlos
Martin-Escudero, Victoria
Oyaguez, Itziar
Ortiz-Maldonado, Valentin
CANCERS, 2024, 16 (13)
[46] Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Lee, Dasom
Kambhampati, Swetha
Bobillo, Maria Silvina Odstrcil
Adedokun, Babatunde
Shadman, Mazyar
Olson, Amanda L.
Herrera, Alex F.
Lee, Catherine J.
Jacobson, Caron A.
Bye, Matthew
Hamadani, Mehdi
Kim, Soyoung
Dahiya, Saurabh
Hu, Zhen-Huan
Speth, Kelly
To, Christina
Mirjah, Debbie L.
Best, Timothy
Locke, Frederick L.
Ahmed, Nausheen
Tees, Michael T.
Pasquini, Marcelo C.
Ahmed, Sairah
BLOOD, 2024, 144 : 527 - 528
[47] Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT
Bachier, Carlos R.
Palomba, M. Lia
Abramson, Jeremy S.
Andreadis, Charalambos
Sehgal, Alison
Godwin, John
Hildebrandt, Gerhard C.
Siddiqi, Tanya
Stevens, Don
Farazi, Thalia
Kostic, Ana
Trede, Nikolaus S.
Wang, Lei
Lymp, James
Thelen, Tennille
Ogasawara, Ken
Maloney, David G.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S25 - S26
[48] Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Kamdar, Manali
Solomon, Scott R.
Arnason, Jon
Johnston, Patrick B.
Glass, Bertram
Bachanova, Veronika
Ibrahimi, Sami
Mielke, Stephan
Mutsaers, Pim
Hernandez-Ilizaliturri, Francisco
Izutsu, Koji
Morschhauser, Franck
Lunning, Matthew
Maloney, David G.
Crotta, Alessandro
Montheard, Sandrine
Previtali, Alessandro
Stepan, Lara
Ogasawara, Ken
Mack, Timothy
Abramson, Jeremy S.
LANCET, 2022, 399 (10343): : 2294 - 2308
[49] AN ECONOMIC MODEL TO ESTIMATE COSTS OF CYTOKINE RELEASE SYNDROME (CRS) AND NEUROLOGICAL EVENTS (NE) AMONG PATIENTS TREATED WITH LISOCABTAGENE MARALEUCEL (LISOCEL) OR AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR SECOND-LINE (2L) TREATMENT OF LARGE B-CELL LYMPHOMA
Badaracco, J.
Ung, B.
Gitlin, M.
Keating, S. J.
VALUE IN HEALTH, 2022, 25 (07) : S368 - S369
[50] Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
Dreger, P.
Westin, J.
Oluwole, O.
Kersten, M. J.
Miklos, D.
Perales, M. -A
Ghobadi, A.
Rapoport, A.
Sureda, A.
Jacobson, C.
Farooq, U.
van Meerten, T.
Ulrickson, M.
Elsawy, M.
Leslie, L.
Chaganti, S.
Dickinson, M.
Yang, Y.
Schupp, M.
To, C.
Locke, F.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 271 - 272

← 1 2 3 4 5 →